We demonstrate an implantable MEMS drug delivery device to conduct controlled and on-demand, ex vivo drug transport to human eye tissue. Remotely operated drug delivery to human post-mortem eyes was performed via a MEMS device. The developed curved packaging cover conforms to the eyeball thereby preventing the eye tissue from contacting the actuating membrane. By pulsed operation of the device, using an externally applied magnetic field, the drug released from the device accumulates in a cavity adjacent to the tissue. As such, docetaxel (DTX), an antiangiogenic drug, diffuses through the eye tissue, from sclera and choroid to retina. DTX uptake by sclera and choroid were measured to be 1.93±0.66 and 7.24±0.37 μg/g tissue, respectively, after two hours in pulsed operation mode (10s on/off cycles) at 23°C. During this period, a total amount of 192 ng DTX diffused into the exposed tissue. This MEMS device shows great potential for the treatment of ocular posterior segment diseases such as diabetic retinopathy by introducing a novel way of drug administration to the eye.
展开▼
机译：我们证明了一种可植入的MEMS药物递送装置，用于对人眼组织进行控制和按需进行控制和按需。通过MEMS器件进行远程操作的药物递送给人验验的眼睛。开发的弯曲包装盖符合眼球，从而防止眼组织接触致动膜。通过装置的脉冲操作，使用外部施加的磁场，从装置中释放的药物累积在与组织相邻的腔中。因此，多西紫杉醇（DTX），抗血管生成药物，通过眼组织扩散，从巩膜和脉络膜到视网膜。巩膜和脉络膜的DTX摄取为1.93＆＃x00b1; 0.66和7.24＆＃x00b1; 0.37＆＃x03bc; g / g组织，在23个脉冲操作模式（10s ON / OFF循环）后2小时后分别在两个小时后＃x00b0; c。在此期间，192个Ng DTX的总量扩散到暴露的组织中。该MEMS装置通过引入眼睛的药物给药新方法，展示了糖尿病视网膜病变如糖尿病视网膜病变的巨大潜力。
展开▼
